<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">MIVACURIUM CHLORIDE</span><br/>(miv-a-cur'i-um)<br/><span class="topboxtradename">Mivacron<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">muscle relaxant</span>; <span class="classification">nondepolarizing</span><br/><b>Prototype: </b>Tubocurarine<br/><b>Pregnancy Category: </b>C<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>0.5 mg/mL, 2 mg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Short-acting, skeletal muscle relaxant that combines competitively to cholinergic receptors on the motor neuron end-plate.
         Antagonizes action of acetylcholine, and blocks neuromuscular transmission. Neuromuscular blocking action is readily reversible
         with an anticholinesterase agent.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Blocks nerve impulse transmission, which results in skeletal muscle relaxation and paralysis.</p>
<h1><a name="uses">Uses</a></h1>
<p>Adjunct to general anesthesia, to facilitate tracheal intubation, and to provide skeletal muscle relaxation during surgery
         or mechanical ventilation.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Allergic reactions to mivacurium or its ingredients.</p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Kidney function impairment, liver function impairment; older adult patients; pregnancy (category C), lactation.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Tracheal Intubation and Mechanical Ventilation</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV Loading Dose</span> 0.15 mg/kg given over 515 sec (over 60 sec in patients with cardiovascular disease) <span class="rdroute">IV Maintenance Dose</span> 0.1 mg/kg generally q15min <span class="rdroute">IV Continuous Infusion</span> Initial infusion of 910 mcg/kg/min, reduce infusion to 4 mcg/kg/min if started with initial bolus<br/><span class="rdage">Child:</span> <span class="rdroute">IV Loading Dose</span>
<i>212 y,</i> 0.2 mg/kg given over 515 sec (range: 0.090.2 mg/kg) <span class="rdroute">IV Maintenance Dose</span> Same as adult <span class="rdroute">IV Continuous Infusion</span> 1015 mcg/kg/min<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> Decrease infusion rates by 50%<br/><br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">Direct:</span> Add 3 mL of D5W, NS, D5/NS, RL, or D5/RL to each 1 mL mivacurium to yield 0.5 mg/mL.  <span class="methodtype">IV Infusion:</span> Available premixed (50 mL of 0.5 mg/mL).  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">Direct:</span> Give over 1560 sec.  <span class="methodtype">IV Infusion:</span> Refer to manufacturer's infusion rate tables. The use of a peripheral nerve stimulator permits optimal dosing and minimizes
                  risks of overdose or underdose.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Solution/additive:</span>
<span class="classification">alkaline solutions</span> pH &gt;8.5 (<span class="classification">barbiturates</span>). 
               </p>
</td>
</tr>
</table>
<ul>
<li>Store diluted solution at 5°25° C (41°77° F) for up to 24 h.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> Transient decrease in arterial BP, hypotension, increases and decreases in heart rate. <span class="typehead">Skin:</span>
<span class="speceff-common">Transient flushing about the face, neck, and/or chest</span> (especially with rapid administration). 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<span class="classification">general anesthetics</span>
<b>(enflurane,</b>
<b>halothane,</b>
<b>isoflurane)</b> may enhance the degree of neuromuscular blockade produced by mivacurium. <span class="classification">aminoglycosides</span>, <span class="classification">tetracyclines</span>, <b>bacitracin,</b>
<span class="classification">polymyxins</span>, <b>lincomycin,</b>
<b>clindamycin,</b>
<b>colistin,</b>
<b>magnesium salts,</b>
<b>lithium,</b>
<span class="classification">local anesthetics</span>, <b>procainamide,</b> and <b>quinidine</b> may enhance the neuromuscular blockade. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead"> Peak:</span>  26 min. <span class="typehead">Duration:</span> 2530 min in adults, 816 min in children. <span class="typehead">Distribution:</span> Limited tissue distribution. <span class="typehead">Metabolism:</span> Rapidly hydrolyzed by plasma cholinesterase. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Assess patients with neuromuscular disease carefully and adjust drug dosage using a peripheral nerve stimulator when they
            experience prolonged neuromuscular blocks.
         </li>
<li>Monitor hemodynamic status carefully in patients with significant cardiovascular disease or those with potentially greater
            sensitivity to release of histamine-type mediators (e.g., asthma).
         </li>
<li>Monitor for significant drop in BP because overdose may increase the risk of hemodynamic adverse effects.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>